Hims & Hers Launches Peptides+ Cellular Health Service as HIMS Stock Slips to $17.04
Key Takeaways
- •Hims & Hers launched Peptides+ on November 18 as a new cellular health and wellness specialty within its telehealth platform.
- •The specialty debuts with five treatments—Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine—supplied through licensed U.S. compounding pharmacies.
- •The company plans to add BPC-157 and TB-500 as the specialty expands, with access aligned to applicable U.S. regulatory standards.
- •HIMS shares fell 2.93% to $17.04, a decline of $0.51, on the same day the launch was announced.
- •The accompanying Care+ program provides eligible customers with laboratory testing twice annually and continuous messaging access to providers trained in peptide therapies.

Hims & Hers Health, Inc. (NYSE: HIMS) has launched Peptides+, a new specialty that extends the company's personalized healthcare services into cellular health and wellness. The offering debuts with five treatments delivered through licensed medical providers, with additional therapies planned under applicable regulatory requirements. The launch was announced on November 18, the same day HIMS shares fell 2.93% to $17.04, a decline of $0.51 amid continued selling pressure during afternoon trading. The introduction marks the company's entry into cellular health as a distinct specialty within its telehealth platform.
Peptides+ Debuts With Five Treatments
With the November 18 introduction of Peptides+, Hims & Hers is expanding its telehealth platform beyond its existing treatment categories. The company said the new specialty combines personalized treatment plans with clinical assessments and ongoing support from licensed healthcare professionals, and that it aims to improve customer access to emerging therapies through its established digital healthcare network.
At launch, Peptides+ offers five treatments — Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine — supplied through licensed U.S. compounding pharmacies. According to the company, Sermorelin supports growth hormone signaling, while NAD+ plays a role in cellular energy production and DNA repair. Glutathione supports antioxidant functions, and Vitamin B12 and L-Carnitine contribute to normal metabolic processes. The descriptions position the specialty as a wellness-oriented offering, with each compound presented in terms of its supporting role in cellular and metabolic functions.
Access to treatment begins with a required medical assessment. Providers review each customer's medical history, health conditions, and individual goals before determining eligibility and developing an appropriate treatment plan. Care teams then monitor patient progress and adjust treatment protocols according to clinical needs and individual responses.
Care+ Pairs Treatment With Lab Testing and Medical Support
The Peptides+ specialty operates alongside Care+, a program that combines healthcare treatments with laboratory testing and ongoing medical guidance. Under the program, eligible customers receive laboratory testing twice annually and gain access to dedicated healthcare support teams. Customers can also contact providers trained in peptide therapies through continuous messaging access.
For men, the Hims health panel offers at-home blood collection and testing across 22 health biomarkers, including testosterone, cholesterol, and vitamin D levels. These measurements provide additional information about individual health conditions, and customers with relevant laboratory results can consult providers about potential eligibility for testosterone treatment.
For women, Hers has introduced an at-home blood collection option through its dedicated health panel, which measures 22 biomarkers covering hormone levels, vitamin status, and cardiovascular health indicators. The company said these offerings expand its laboratory services while integrating additional testing into its personalized healthcare platform.
Planned Expansion Under Regulatory Standards
Hims & Hers plans to introduce BPC-157 and TB-500 as the Peptides+ specialty expands beyond its initial offerings, with access to the treatments aligned to applicable U.S. regulatory standards. The planned additions represent another stage in the company's expansion into emerging healthcare treatment categories. How these planned therapies become accessible under the applicable regulatory framework will offer a concrete marker of the specialty's development beyond its initial five treatments.
Hims & Hers currently provides telehealth services across several categories, including dermatology, sexual health, and weight management. Peptides+ adds another specialty to this model by combining remote consultations, treatment delivery, and medical follow-up services. Licensed U.S. pharmacies will compound and dispense prescribed treatments under applicable state pharmacy regulations.
The launch also broadens the company's focus on personalized healthcare built on laboratory insights and provider-led treatment decisions. Its integrated approach connects medical assessments, testing, prescriptions, and ongoing patient communication within a single digital platform, expanding the Hims & Hers service portfolio as the company moves into additional healthcare categories.
Source: Blockonomi